Valneva (NASDAQ:VALN) Price Target Lowered to $13.00 at Guggenheim

Key Points

• Guggenheim has lowered its price target for Valneva's stock from $14.00 to $13.00, while maintaining a "buy" rating, indicating a potential upside of 55.97% from the previous closing price.
• Other brokerages have also issued varying ratings, with Jefferies Financial Group setting a price target of $14.00 and HC Wainwright issuing a target of $18.00, reflecting a consensus rating of "buy".
• Valneva reported a loss of ($0.16) earnings per share for the quarter, exceeding analyst expectations, and had a revenue of $54.84 million compared to estimates of $46.28 million.

Valneva (NASDAQ:VALN - Get Free Report) had its target price reduced by stock analysts at Guggenheim from $14.00 to $13.00 in a research note issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Guggenheim's price target indicates a potential upside of 55.97% from the company's previous close.

A number of other brokerages have also recently issued reports on VALN. Jefferies Financial Group set a $14.00 price target on shares of Valneva and gave the stock a "buy" rating in a research note on Monday, August 25th. Wall Street Zen raised shares of Valneva to a "hold" rating in a report on Saturday. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Valneva in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $15.00.

Valneva Stock Down 3.6%

Shares of NASDAQ VALN opened at $8.34 on Monday. The company has a quick ratio of 1.77, a current ratio of 2.27 and a debt-to-equity ratio of 0.66. Valneva has a 52 week low of $3.62 and a 52 week high of $12.25. The firm's fifty day moving average is $8.03 and its 200 day moving average is $7.07. The company has a market cap of $716.23 million, a price-to-earnings ratio of -8.51 and a beta of 1.78.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $54.84 million for the quarter, compared to the consensus estimate of $46.28 million. Valneva had a negative net margin of 33.87% and a negative return on equity of 34.78%. On average, equities research analysts expect that Valneva will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Marex Group plc purchased a new stake in shares of Valneva in the second quarter valued at approximately $64,000. GAMMA Investing LLC acquired a new stake in shares of Valneva in the 1st quarter worth $94,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Valneva in the 2nd quarter worth $8,240,000. 11.39% of the stock is owned by institutional investors and hedge funds.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.